NCT03603808View on ClinicalTrials.gov

VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

September 21, 2018

Primary Completion Date

December 31, 2024

Study Completion Date

June 17, 2025

Conditions
Anal Intraepithelial NeoplasiaHigh Grade Squamous Intraepithelial NeoplasiaHIV PositivityHuman Papillomavirus-16 PositiveHuman Papillomavirus-18 Positive
Interventions
DEVICE

Electroporation

Undergo electroporation

BIOLOGICAL

HPV DNA Plasmids Therapeutic Vaccine VGX-3100

Given IM

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (8)

10011

Laser Surgery Care, New York

10461

Montefiore Medical Center, The Bronx

27157

Wake Forest Baptist health Sciences, Winston-Salem

30303

Grady Health System, Atlanta

60614

Anal Dysplasia Clinic MidWest, Chicago

94143

University of California, San Francisco, San Francisco

02118

Boston Medical Center, Boston

00936-3027

University of Puerto Rico, San Juan

Sponsors

Collaborators (1)

Inovio Pharmaceuticals
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

The Emmes Company, LLC

INDUSTRY

collaborator

Inovio Pharmaceuticals

INDUSTRY

lead

AIDS Malignancy Consortium

NETWORK

NCT03603808 - VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions | Biotech Hunter | Biotech Hunter